In May, the FDA granted significant drug approvals across various therapeutic areas, marking notable progress in expanding treatment options for patients.

Hyperpolarized xenon MRI may be useful in assessing response to biologic treatment among patients with asthma, according to a ...

The benefits of 52-week biologic therapy on asthma control and lung function are observed in both never smokers and ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat CRSwNP in 2019, and was joined on the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

Black patients tend to experience more aggressive instances of MS and face greater barriers to diagnosis and treatment.

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

Genetics and poor healthcare contribute to Black men's prostate cancer disparities. Unequal care, not biology, is the root ...

Bagnasco has received speaker’s honoraria and advisory board membership from AstraZeneca, Chiesi, Firma, GSK, Novartis, Menarini, Sanofi, and Zambon. Berti has received funding from GSK for advisory ...